First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer A Meta-Analysis 英文参考文献.docVIP

下载本文档

6
0
约2.49万字
约 7页
2017-05-11 发布于上海
举报
版权申诉

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer A Meta-Analysis 英文参考文献.doc

1、本文档共7页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer A Meta-Analysis 英文参考文献

FirstEfficacyResultsofCapecitabinewithAnthracycline- andTaxane-BasedAdjuvantTherapyinHigh-RiskEarly BreastCancer:AMeta-Analysis YiweiJiang1.,WenjinYin2.,LihengZhou2,TingtingYan1,QiongZhou1,YueyaoDu1,ZhenzhouShen2, ZhiminShao2,JinsongLu2* 1DepartmentofOncology,ShanghaiMedicalCollege,FudanUniversity,Shanghai,People’sRepublicofChina,2DepartmentofBreastSurgery,FudanUniversityShanghai CancerCenter,Shanghai,People’sRepublicofChina Abstract Background:Capecitabineiseffectiveandindicatedforthesalvagetreatmentofmetastaticbreastcancer.Therefore,itis essentialtoevaluatetheefficacyofcapecitabineintheadjuvantsetting.Therehavebeentwolargerandomizedstudiesto determine whether patients with high-risk early breast cancer benefit from the addition of capecitabine to standard chemotherapy,buttheyhaveyieldedinconsistentresults.Wefirstundertookameta-analysistoevaluatetheefficacyofthe additionofcapecitabineoverstandardtreatment. Methods:PubMed,EBSCO,WebofScience,conferenceproceedingsandkeytrialsweresearchedfrom1998to2011.The hazard ratio (HR) was used to evaluate the efficacy of a taxane-anthracycline regimen and a taxane-anthracycline- capecitabineregimeninearlybreastcancer.Allofthedatafromeachstudyuseeitherfixed-effectsorrandom-effectsby Stata. Findings:Wefoundsignificantimprovementintheadditionalcapecitabinearmversuscontrolindisease-freesurvival(DFS) (HR=0.83, 95% CI: 0.71–0.98, P=0.027), overall survival (OS) (HR=0.71, 95% CI: 0.57–0.88, P=0.002), distant recurrence (HR=0.79, 95% CI: 0.66–0.94, P=0.008) and the death from breast cancer only (HR=0.65, 95% CI: 0.51–0.83, P=0.001). Meanwhile,thesubgroupanalysisrevealedthatcapecitabineimprovedtheDFSintriplenegative(HR=0.71,95%CI:0.53– 0.96,P=0.028),hormonereceptornegative(HR=0.73,CI:0.56–0.94,P=0.017)andHER2negative(HR=0.81,CI:0.67–0.98, P=0.034)patients. Conclusion: Due to the synergistic effect of taxane and capecitabine, taxane-anthracycline-capecitabine regimen may effectivelyimprovetheefficacyintheadjuvantsettingandmaybeanovelgene